A gradual taper or dose reduction, rather than stopping abruptly, may help your body adjust
Semaglutide and liraglutide, which were initially approved for the treatment of type 2 diabetes, have since been approved by the Food and Drug Administration as weight loss medications due to their effectiveness in promoting significant and sustained weight loss
This drug also activates glucose-dependent insulinotropic polypeptide (GIP) as well as GLP1
The pain report provides valuable insights for individuals with a history of physical trauma, as well as those experiencing musculoskeletal, neuropathic pain, fibromyalgia, and arthritis, including osteoarthritis and rheumatoid arthritis
A.ScisciolaL.PesapaneA.TaktazF.FranzeseM.et al (2023)
Considerations: Update disclosure questions and underwriting practices to better capture policyholder health trajectories